These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1258 related articles for article (PubMed ID: 30215381)
1. Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: an individual patient data meta-analysis. ; Ahmad N; Ahuja SD; Akkerman OW; Alffenaar JC; Anderson LF; Baghaei P; Bang D; Barry PM; Bastos ML; Behera D; Benedetti A; Bisson GP; Boeree MJ; Bonnet M; Brode SK; Brust JCM; Cai Y; Caumes E; Cegielski JP; Centis R; Chan PC; Chan ED; Chang KC; Charles M; Cirule A; Dalcolmo MP; D'Ambrosio L; de Vries G; Dheda K; Esmail A; Flood J; Fox GJ; Fréchet-Jachym M; Fregona G; Gayoso R; Gegia M; Gler MT; Gu S; Guglielmetti L; Holtz TH; Hughes J; Isaakidis P; Jarlsberg L; Kempker RR; Keshavjee S; Khan FA; Kipiani M; Koenig SP; Koh WJ; Kritski A; Kuksa L; Kvasnovsky CL; Kwak N; Lan Z; Lange C; Laniado-Laborín R; Lee M; Leimane V; Leung CC; Leung EC; Li PZ; Lowenthal P; Maciel EL; Marks SM; Mase S; Mbuagbaw L; Migliori GB; Milanov V; Miller AC; Mitnick CD; Modongo C; Mohr E; Monedero I; Nahid P; Ndjeka N; O'Donnell MR; Padayatchi N; Palmero D; Pape JW; Podewils LJ; Reynolds I; Riekstina V; Robert J; Rodriguez M; Seaworth B; Seung KJ; Schnippel K; Shim TS; Singla R; Smith SE; Sotgiu G; Sukhbaatar G; Tabarsi P; Tiberi S; Trajman A; Trieu L; Udwadia ZF; van der Werf TS; Veziris N; Viiklepp P; Vilbrun SC; Walsh K; Westenhouse J; Yew WW; Yim JJ; Zetola NM; Zignol M; Menzies D Lancet; 2018 Sep; 392(10150):821-834. PubMed ID: 30215381 [TBL] [Abstract][Full Text] [Related]
2. Drug-associated adverse events in the treatment of multidrug-resistant tuberculosis: an individual patient data meta-analysis. Lan Z; Ahmad N; Baghaei P; Barkane L; Benedetti A; Brode SK; Brust JCM; Campbell JR; Chang VWL; Falzon D; Guglielmetti L; Isaakidis P; Kempker RR; Kipiani M; Kuksa L; Lange C; Laniado-Laborín R; Nahid P; Rodrigues D; Singla R; Udwadia ZF; Menzies D; Lancet Respir Med; 2020 Apr; 8(4):383-394. PubMed ID: 32192585 [TBL] [Abstract][Full Text] [Related]
3. Nine months of bedaquiline, linezolid, levofloxacin, clofazimine, and cycloserine chemotherapy for rifampicin/multidrug-resistant tuberculosis: a multicenter, randomized, open-label non-inferiority trial in China. Song Y; Shu W; Pei Y; Du J; Wu G; Wang H; Mi F; Liu F; Ma L; Xie L; Kong Z; Wu X; Liu R; Chen H; Li H; Ge Q; Nie L; Lv Z; Huang X; Li M; Jiang M; Chen X; Cai Q; Chen W; Liu Y; Miao Y; Tang Y; Chen Y; Geng S; Zhou Q; Liu Y; Pang Y; Gao M BMC Med; 2024 Sep; 22(1):401. PubMed ID: 39300460 [TBL] [Abstract][Full Text] [Related]
4. Mortality in adults with multidrug-resistant tuberculosis and HIV by antiretroviral therapy and tuberculosis drug use: an individual patient data meta-analysis. Bisson GP; Bastos M; Campbell JR; Bang D; Brust JC; Isaakidis P; Lange C; Menzies D; Migliori GB; Pape JW; Palmero D; Baghaei P; Tabarsi P; Viiklepp P; Vilbrun S; Walsh J; Marks SM Lancet; 2020 Aug; 396(10248):402-411. PubMed ID: 32771107 [TBL] [Abstract][Full Text] [Related]
5. Effectiveness and safety of modified fully oral 9-month treatment regimens for rifampicin-resistant tuberculosis: a prospective cohort study. Korotych O; Achar J; Gurbanova E; Hovhannesyan A; Lomtadze N; Ciobanu A; Skrahina A; Dravniece G; Kuksa L; Rich M; Khachatryan N; Germanovych M; Kadyrov A; Terleieva I; Akhundova I; Adenov M; Durdyeva M; Kiria N; Parpieva N; Yatskevich N; Jumayev R; Nurov R; Diktanas S; Vilc V; Migliori GB; Yedilbayev A Lancet Infect Dis; 2024 Oct; 24(10):1151-1161. PubMed ID: 38880112 [TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness of adding novel or group 5 interventions to a background regimen for the treatment of multidrug-resistant tuberculosis in Germany. Wirth D; Dass R; Hettle R BMC Health Serv Res; 2017 Mar; 17(1):182. PubMed ID: 28270207 [TBL] [Abstract][Full Text] [Related]
8. Provisional CDC guidelines for the use and safety monitoring of bedaquiline fumarate (Sirturo) for the treatment of multidrug-resistant tuberculosis. Centers for Disease Control and Prevention MMWR Recomm Rep; 2013 Oct; 62(RR-09):1-12. PubMed ID: 24157696 [TBL] [Abstract][Full Text] [Related]
9. World Health Organization 2018 treatment guidelines for rifampicin-resistant tuberculosis: uncertainty, potential risks and the way forward. Van Deun A; Decroo T; Tahseen S; Trébucq A; Schwoebel V; Ortuno-Gutierrez N; de Jong BC; Rieder HL; Piubello A; Chiang CY Int J Antimicrob Agents; 2020 Jan; 55(1):105822. PubMed ID: 31626907 [TBL] [Abstract][Full Text] [Related]
10. Synergistic activities of clofazimine with moxifloxacin or capreomycin against Mycobacterium tuberculosis in China. Li G; Xu Z; Jiang Y; Liu H; Zhao LL; Li M; Xu D; Zhao X; Liu Z; Wang R; Wan K Int J Antimicrob Agents; 2019 Nov; 54(5):642-646. PubMed ID: 31200023 [TBL] [Abstract][Full Text] [Related]
11. Best drug treatment for multidrug-resistant and extensively drug-resistant tuberculosis. Caminero JA; Sotgiu G; Zumla A; Migliori GB Lancet Infect Dis; 2010 Sep; 10(9):621-9. PubMed ID: 20797644 [TBL] [Abstract][Full Text] [Related]
12. Safety and Effectiveness of 3 Novel All-Oral Shortened Regimens for Rifampicin- or Multidrug-Resistant Tuberculosis in Kazakhstan. Rashitov M; Franke MF; Trevisi L; Bekbolatova G; Shalimova J; Eshmetov G; Bektasov S; LaHood A; Arlyapova N; Osso E; Yedilbayev A; Korotych O; Ciobanu A; Skrahina A; Mitnick CD; Seung KJ; Algozhin Y; Rich ML Clin Infect Dis; 2024 Oct; 79(4):1046-1053. PubMed ID: 38833593 [TBL] [Abstract][Full Text] [Related]
13. High treatment success rate for multidrug-resistant and extensively drug-resistant tuberculosis using a bedaquiline-containing treatment regimen. Ndjeka N; Schnippel K; Master I; Meintjes G; Maartens G; Romero R; Padanilam X; Enwerem M; Chotoo S; Singh N; Hughes J; Variava E; Ferreira H; Te Riele J; Ismail N; Mohr E; Bantubani N; Conradie F Eur Respir J; 2018 Dec; 52(6):. PubMed ID: 30361246 [TBL] [Abstract][Full Text] [Related]
14. Assessment of epidemiological and genetic characteristics and clinical outcomes of resistance to bedaquiline in patients treated for rifampicin-resistant tuberculosis: a cross-sectional and longitudinal study. Ismail NA; Omar SV; Moultrie H; Bhyat Z; Conradie F; Enwerem M; Ferreira H; Hughes J; Joseph L; Kock Y; Letsaolo V; Maartens G; Meintjes G; Ngcamu D; Okozi N; Padanilam X; Reuter A; Romero R; Schaaf S; Te Riele J; Variava E; van der Meulen M; Ismail F; Ndjeka N Lancet Infect Dis; 2022 Apr; 22(4):496-506. PubMed ID: 34780706 [TBL] [Abstract][Full Text] [Related]
15. Comparison of different treatments for isoniazid-resistant tuberculosis: an individual patient data meta-analysis. Fregonese F; Ahuja SD; Akkerman OW; Arakaki-Sanchez D; Ayakaka I; Baghaei P; Bang D; Bastos M; Benedetti A; Bonnet M; Cattamanchi A; Cegielski P; Chien JY; Cox H; Dedicoat M; Erkens C; Escalante P; Falzon D; Garcia-Prats AJ; Gegia M; Gillespie SH; Glynn JR; Goldberg S; Griffith D; Jacobson KR; Johnston JC; Jones-López EC; Khan A; Koh WJ; Kritski A; Lan ZY; Lee JH; Li PZ; Maciel EL; Galliez RM; Merle CSC; Munang M; Narendran G; Nguyen VN; Nunn A; Ohkado A; Park JS; Phillips PPJ; Ponnuraja C; Reves R; Romanowski K; Seung K; Schaaf HS; Skrahina A; Soolingen DV; Tabarsi P; Trajman A; Trieu L; Banurekha VV; Viiklepp P; Wang JY; Yoshiyama T; Menzies D Lancet Respir Med; 2018 Apr; 6(4):265-275. PubMed ID: 29595509 [TBL] [Abstract][Full Text] [Related]
16. TB-PRACTECAL: study protocol for a randomised, controlled, open-label, phase II-III trial to evaluate the safety and efficacy of regimens containing bedaquiline and pretomanid for the treatment of adult patients with pulmonary multidrug-resistant tuberculosis. Berry C; du Cros P; Fielding K; Gajewski S; Kazounis E; McHugh TD; Merle C; Motta I; Moore DAJ; Nyang'wa BT Trials; 2022 Jun; 23(1):484. PubMed ID: 35698158 [TBL] [Abstract][Full Text] [Related]
18. Impact and cost-effectiveness of the 6-month BPaLM regimen for rifampicin-resistant tuberculosis in Moldova: A mathematical modeling analysis. James LP; Klaassen F; Sweeney S; Furin J; Franke MF; Yaesoubi R; Chesov D; Ciobanu N; Codreanu A; Crudu V; Cohen T; Menzies NA PLoS Med; 2024 May; 21(5):e1004401. PubMed ID: 38701084 [TBL] [Abstract][Full Text] [Related]
19. Delamanid, linezolid, levofloxacin, and pyrazinamide for the treatment of patients with fluoroquinolone-sensitive multidrug-resistant tuberculosis (Treatment Shortening of MDR-TB Using Existing and New Drugs, MDR-END): study protocol for a phase II/III, multicenter, randomized, open-label clinical trial. Lee M; Mok J; Kim DK; Shim TS; Koh WJ; Jeon D; Lee T; Lee SH; Kim JS; Park JS; Lee JY; Kim SY; Lee JH; Jo KW; Jhun BW; Kang YA; Ahn JH; Kim CK; Shin S; Song T; Shin SJ; Kim YR; Ahn H; Hahn S; Won HJ; Jang JY; Cho SN; Yim JJ Trials; 2019 Jan; 20(1):57. PubMed ID: 30651149 [TBL] [Abstract][Full Text] [Related]
20. Treatment outcomes 24 months after initiating short, all-oral bedaquiline-containing or injectable-containing rifampicin-resistant tuberculosis treatment regimens in South Africa: a retrospective cohort study. Ndjeka N; Campbell JR; Meintjes G; Maartens G; Schaaf HS; Hughes J; Padanilam X; Reuter A; Romero R; Ismail F; Enwerem M; Ferreira H; Conradie F; Naidoo K; Menzies D Lancet Infect Dis; 2022 Jul; 22(7):1042-1051. PubMed ID: 35512718 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]